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Epigenetic variants have been shown in recent studies to be important contributors to the
pathogenesis of systemic lupus erythematosus (SLE). Here, we report a 2-step study of dis-
covery followed by replication to identify DNA methylation alterations associated with SLE in
a Chinese population. Using a genome-wide DNA methylation microarray, the Illumina Infi-
nium HumanMethylation450 BeadChip, we compared the methylation levels of CpG sites in
DNA extracted from white blood cells from 12 female Chinese SLE patients and 10 healthy
female controls.
Results
We identified 36 CpG sites with differential loss of DNA methylation and 8 CpG sites with dif-
ferential gain of DNA methylation, representing 25 genes and 7 genes, respectively. Surpris-
ingly, 42% of the hypomethylated CpG sites were located in CpG shores, which indicated
the functional importance of the loss of DNA methylation. Microarray results were replicated
in another cohort of 100 SLE patients and 100 healthy controls by performing bisulfite pyro-
sequencing of four hypomethylated genes, MX1, IFI44L, NLRC5 and PLSCR1. In addition,
loss of DNA methylation in these genes was associated with an increase in mRNA expres-
sion. Gene ontology analysis revealed that the hypomethylated genes identified in the
microarray study were overrepresented in the type I interferon pathway, which has long
been implicated in the pathogenesis of SLE.
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Conclusion
Our epigenetic findings further support the importance of the type I interferon pathway in
SLE pathogenesis. Moreover, we showed that the DNA methylation signatures of SLE can
be defined in unfractionated white blood cells.
Introduction
Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with significant
morbidity and mortality. The prevalence of SLE is higher in Asians (58.8/100,000) than in
Caucasians (20.7/100,000) [1, 2]. SLE is characterized by abnormal T-cell and B-cell signaling,
with auto-antibodies against nuclear antigens such as DNA, histones and nucleosomes [3, 4].
Genome-wide association studies have shown that the development of SLE is associated with
variants in multiple genes, such as PXK, ITGAM, CD80 and CDKN1B [5–7].
Apart from genetic factors, environmental factors such as ultraviolet B radiation, viral infec-
tions and drugs such as hydralazine or procainamide can lead to SLE [8–10]. In particular,
environmental factors exert their effect through DNA methylation changes [11]. DNA methyl-
ation usually occurs on cytosine residues of cytosine-guanosine dinucleotides (CpG), and this
modification can act as a transcriptional regulator. Methylation of CpG sites in the promoter
region usually causes gene silencing [12]. In addition, CpG island shores (CpG shores) are
defined as regions that are 0–2 kb away from a CpG island and are associated with most tissue-
specific differential DNA methylation, rather than CpG islands, and the DNA methylation
level in CpG shores is inversely related to gene expression [13].
A number of observations in T cells from patients with SLE have demonstrated the targeted
loss of DNA methylation and overexpression of specific genes relevant to autoimmunity, lead-
ing to autoreactivity, excessive B-cell stimulation and cytotoxicity. The first evidence that
lupus-associated drugs such as procainamide and hydralazine could inhibit DNA methylation
was reported in 1988 [9]. It was later demonstrated that hypomethylation of the CpG sites
within the regulatory sequence of ITGALwas observed in T cells from individuals who were
treated with lupus-associated drugs, resulting in over-expression of CD11a [14]. This hypo-
methylation was also observed in T cells of SLE patients. CD11a strengthens the adhesion of T
cells to other immune cells and thereby likely contributes to autoreactivity. Later, it was found
that the promoter region of PRF1 is hypomethylated in CD4+ T cells from lupus patients, lead-
ing to over-expression of perforin, which is a cytotoxic molecule of natural killer cells and
cytotoxic T cells [15]. The promoter region of CD70was also found to be hypomethylated in
SLE patients, leading to over-expression of CD70. This phenomenon was also observed in cells
treated with DNA methylation inhibitors [16]. Lastly, the X-linked gene TNFSF5, encoding the
CD40 ligand, which is important in T cell-dependent B-cell stimulation, is also hypomethy-
lated and over-expressed in T cells of lupus patients [17].
In addition to targeted studies of DNA hypomethylation in gene promoter regions, several
studies have investigated the genome-wide DNA methylation status in SLE patients. These
studies utilized different versions of the Illumina microarray platform and included SLE
patients of mixed ethnicity. Although these studies showed hypomethylation of genes, they
were enriched in different biological pathways. For example, with the use of the HumanMethy-
lation27 BeadChip, Jeffries et al. found hypomethylated genes that were related to growth of
cells, apoptosis, developmental tissue processes and cell activation [18], and Ho et al. identified
genes involved in cellular movement and immune cell trafficking [19]. However, more recent
studies utilizing the HumanMethylation450 BeadChip (450k microarray) demonstrated that
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genes in the interferon pathway were persistently hypomethylated in various specific blood
cell lineages [20–22].
Since DNA methylation can be affected by single nucleotide polymorphisms as well as the
ethnic background of individuals [23], we undertook the first study of genome-wide DNA
methylation changes in SLE patients of Chinese ethnicity using the 450k microarray, with the
aim of identifying DNA methylation changes specific to Chinese ethnicity, where the preva-
lence of SLE is higher than in other populations. In fact, our findings in Chinese SLE patients
replicated the results in previous studies indicating that hypomethylation occurred in genes
related to the type I interferon pathway, which has long been implicated in the pathogenesis of
SLE [24].
Materials and Methods
Patient selection and healthy controls
The SLE patients who participated in this study were all female and self-reported to be of Chi-
nese ethnicity living in Hong Kong. These patients all met the criteria of the American College
of Rheumatology for SLE diagnosis [25] and were over 16 years old at the time of disease
onset. One additional requirement for SLE patients recruited in the microarray study was that
patients within 4 years of diagnosis were selected to minimize the effect of pharmacologic
treatment on DNA methylation patterns, as per Javierre et al. [26]. However, patients recruited
for validation and replication by bisulfite pyrosequencing and mRNA expression analysis did
not necessarily fulfill this additional requirement due to the limited number of patients. Each
SLE patient was compared to sex-, age- and ethnicity-matched controls. Blood samples from
healthy controls were obtained from the Hong Kong Red Cross, and these participants were
self-reported to be healthy without chronic diseases. Written consent was obtained and kept in
the patients’ clinical charts, which were stored by the corresponding hospitals from which the
patients were recruited. This study was approved by the Institutional Review Board of the Uni-
versity of Hong Kong/Hospital Authority Hong Kong West Cluster (IRB Ref: UW10-380).
Whole genome DNA methylation microarray
Twelve patients with SLE and 12 healthy controls were studied using the HumanMethyla-
tion450 BeadChip (Illumina) for genome-wide DNA methylation analysis. The clinical infor-
mation of the 12 patients with SLE can be found in S1 Table. The microarray targets ~485,000
CpG sites spanning 30,000 genes, covering 99% of RefSeq genes. It provides broad coverage
throughout gene regions including 1.5 kb or 2 kb upstream of the transcription start site and
the five prime untranslated region (5’UTR), first exon, gene body and three prime untranslated
region (3’ UTR), as well as CpG islands and the surrounding shelves and shores, for a compre-
hensive view of methylation levels. CpG island refers to a region of at least 2 kb with a CG con-
tent of greater than 50%, a CpG island shore (CpG shore) is the region 0 to 2 kb away from the
CpG island, a CpG island shelf (CpG shelf) is the region 2 to 4 kb away from the CpG island,
and regions that do not belong to either a CpG island, CpG shore or CpG shelf are referred to
as non-islands. DNA was extracted from whole blood using the FlexiGene DNA Kit according
to the manufacturer’s protocol (Qiagen). DNA samples were then bisulfite-converted using
the EpiTect Bisulfite Kit according to the manufacturer’s protocol (Qiagen). Bisulfite-con-
verted DNA was labeled, hybridized and scanned at the Centre for Applied Genomics at The
Hospital for Sick Children, Toronto, Canada. Intensities were normalized using Illumina’s
internal normalization probes and algorithms. Beta values were derived from intensities as
defined by the ratio of methylated to unmethylated probes given by β = M/ (U+M+100) and
were used as a measure of the effect size. Data quality was assessed using Genome Studio
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(Illumina) for data quality control and exported into the R statistical environment and assessed
by Illumina Methylation Analyzer package for differential methylation analysis. Loci with
missing beta values and with a median detection p-value > 0.01 were filtered for further analy-
sis. For each specific region, the Wilcoxon rank-sum test was used for group comparisons, and
the false discovery rate control was used for multiple testing corrections. CpG sites with an
adjusted p-value < 0.05 and a mean methylation change> |0.1| were considered differentially
methylated.
To evaluate the potential effect of blood cell type composition on the identified differentially
methylated CpG sites, the DNA methylation profile of our samples was compared to that of
different blood fractions from a study by Reinius et al. [27], which are available from the GEO
repository (series GSE35069). The DNA methylation data of Reinius et al. included whole
blood, peripheral blood mononuclear cells (PBMCs) and granulocytes, as well as isolated cell
populations including CD4+ T cells, CD8+ T cells, CD56+ NK cells, CD19+ B cells, and CD14
+ monocytes. We compared the 60 samples (each type of blood fraction contained 6 samples)
from the Reinius et al. study to our 12 SLE and 10 control samples by principal component
analysis, restricting the analysis to the differentially methylated CpG sites identified in SLE.
Bisulfite pyrosequencing
An additional cohort of 100 SLE patients and 100 healthy controls were recruited to replicate the
microarray results. The DNA methylation level was measured by bisulfite pyrosequencing as
described [28]. In short, pyrosequencing assays containing 2 PCR primers and 1 sequencing
primer were designed to target CpG sites of interest using PyroMark Assay Design Software (Qia-
gen). Genomic DNA was sodium bisulfite-converted as described above for the Illumina micro-
array and amplified using Hot-Start Taq polymerase (Qiagen). The amplicons were analyzed on
a Q24 pyrosequencer (Qiagen) as specified by the manufacturer, and the percent of methylation
was quantified as the ratio of C to C+T using PyroMark Q24 Software (Qiagen). The pyrosequen-
cing of LINE-1 was performed using a PyroMark Q24 CpG LINE-1 assay (Qiagen). The assay
design for the four genes selected from the 450k microarray results can be found in S2 Table, and
the sequences flanking the differentially methylated CpG sites are shown in S1 Fig.
Gene ontology annotation analysis
Gene Ontology annotation analysis was performed using GeneMANIA (University of Toronto,
www.genemania.org) [29]. Both hypomethylated and hypermethylated genes identified in the
microarray study were input separately into GeneMANIA for co-expression analysis. GeneMA-
NIA uses many publicly available biological databases to identify any interactions among the
input gene list, such as protein and genetic interactions, pathways, co-localization and co-
expression.
Real-time PCR gene expression study
Real-time PCR was performed to quantify the expression of MX1, IFI44L,NLRC5 and
PLSCR1. The relative amount of mRNA from 100 healthy controls and 100 SLE patients was
quantitated by real-time polymerase chain reaction. An amount of 1 μg of total RNA was
reverse transcribed using High-Capacity cDNA Reverse Transcription Kits (Applied Biosys-
tems) according to the manufacturer’s protocol. cDNA was amplified by TaqMan-based real-
time PCR on an Applied Biosystems 7900HT real-time PCR system according to the instruc-
tions of the manufacturer (TaqMan Gene Expression Assay). For each sample, gene expression
was normalized against the expression of an endogenous control, the glyceraldehyde-3-phos-
phate dehydrogenase gene.
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Statistical analysis
Unless otherwise specified, Student’s t-test was performed to assess the significance between
the two groups, controls and SLE patients. A p-value< 0.05 was considered statistically signifi-
cant. Analysis was performed by SPSS Statistics version 19 (IBM).
Results
Identification of differentially methylated CpG sites in SLE patients
The genome-wide DNA methylation status of 12 female SLE patients and 12 female healthy
controls was analyzed using the 450k microarray. Two control samples were excluded from
further analysis as they did not meet the requirements for quality control in our study. There
was no significant difference between the average β of the 485,577 CpG sites detected by the
microarray in controls and SLE patients (S2 Fig). To further investigate the global DNA meth-
ylation level in SLE patients, bisulfite pyrosequencing was carried out on the long interspersed
nucleotide element-1 (LINE-1) of the 10 controls and 12 SLE patients. The DNA methylation
levels of three different CpG sites overlapping LINE-1were investigated, and there was no sig-
nificant difference between the average methylation levels of LINE-1 in controls and SLE
patients (p = 0.848, Fig 1).
We then compared the DNA methylation status of SLE patients and controls using the Wil-
coxon rank-sum test for group comparisons and applied corrections for multiple testing.
Among the CpG sites detected by the microarray, there were 1012 CpG sites with an adjusted
p-value < 0.05 and 1294 CpG sites with mean methylation changes > |0.1|. Only CpG sites
that had both an adjusted p-value < 0.05 and a mean methylation change > |0.1| were consid-
ered differentially methylated, and 44 CpG sites fulfilled both criteria. Among the 44 differen-
tially methylated CpG sites, 36 had loss of methylation while 8 showed gain of methylation,
representing 25 and 7 genes, respectively (Fig 2). A full list of these 44 differentially methylated
CpG sites can be found in S3 Table. Visual inspection of the differentially methylated sites
Fig 1. LINE-1 methylation level measurement in control and SLE patients. Bisulfite pyrosequencing was
performed for 10 controls and 12 SLE patients on three different CpG sites in LINE-1 to determine their
average methylation level. There is no significant difference between the average methylation levels of LINE-
1 in controls and SLE patients.
doi:10.1371/journal.pone.0169553.g001
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revealed that some of the hypermethylated genes, although fulfilling the criteria of mean meth-
ylation change> 0.1 and adjusted p-value < 0.05, might not be consistently hypermethylated
in SLE patients. For example, as in the case of MICB, differential hypermethylation was ob-
served because two control samples had much lower average DNA methylation levels than the
other 20 samples (S3 Fig). In contrast, for hypomethylated CpG sites, the differences were
more consistent between the two groups.
We then examined the potential effect of blood cell type composition on the SLE methyla-
tion signature. Data on exact cell type composition are very scarce in general, and we did not
have direct measurements of cell-type composition for our data samples. Instead, we used the
DNA methylation profiles of 60 blood fractions from a previously published study [27]. Princi-
pal component analysis of 44 CpG sites, comparing the SLE-specific signature of our samples
and samples published by Reinius et al. [27], showed a clear separation between the SLE cohort
Fig 2. Heat map visualization of differentially methylated CpG sites. Forty-four differentially methylated CpG
sites of 10 controls and 12 SLE patients are shown. CpG sites are clustered using Manhattan clustering, and the
corresponding gene name of the CpG site is also shown on the left (if any). A scale is shown on the right, in which red
and green correspond to a higher and a lower methylation status, respectively.
doi:10.1371/journal.pone.0169553.g002
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and all normal blood samples, including the different blood fractions (S4 Fig). These results
clearly show that neither the normal whole blood, nor peripheral blood mononuclear cells
(PBMCs), nor any of the cell subtypes isolated from such samples possess the DNA methyla-
tion profile associated with the SLE signature. Nor was the specificity of the SLE signature
affected by the batch difference between our dataset and the dataset of Reinius et al. [27], dem-
onstrating the robustness of the SLE signature and the relevance of using whole blood as a suit-
able clinical material for identifying SLE-specific DNA methylation signatures.
Further, we assessed the position of differentially methylated CpG sites both with respect to
the CpG islands and within the gene. Of the hypomethylated CpG sites, 42% (15 of 36) were
located in CpG shores. However, there was no specific pattern observed for hypermethylated
CpG sites in terms of distribution with respect to CpG islands. Moreover, hypomethylated
CpG sites occurred more frequently upstream of the transcription start site, in the gene body
and in the 5’UTR (17, 10 and 10 sites of 36, respectively), whereas all the hypermethylated
CpG sites were located in gene bodies (Fig 3).
Replication of selected loci in an independent additional cohort
To validate and replicate the differentially methylated CpG sites identified with the 450k
microarray data, bisulfite pyrosequencing was carried out for four hypomethylated genes,
MX1, IFI44L,NLRC5 and PLSCR1, in a larger cohort of 100 controls and 100 SLE patients. The
selection of these genes was based on the relevance of the genes to SLE and innate immunity,
as well as the representation of probes on the microarray. For example, IFI44L has CpG sites
with the largest degree of DNA methylation loss among all the differentially hypomethylated
CpG sites identified, and genes such as NLRC5 and MX1 have multiple probes showing DNA
methylation loss, suggesting that these genes have multiple CpG sites with DNA methylation
loss. The hypomethylated CpG sites of MX1 and PLSCR1 selected for validation were located
in CpG shores, whereas that of NLRC5was located in a CpG island. The tested CpG sites
within these selected genes exhibited a significant loss of methylation in SLE patients when
compared to controls (p< 2.2e-16, Fig 4). For MX1 and NLRC5, pyrosequencing targeted an
additional 6 CpG sites surrounding the one identified by microarray analysis, allowing us to
expand the number of CpG sites with altered DNA methylation (S5 Fig). We found that loss of
DNA methylation was not limited to the particular CpG site that was detected by microarray
but could also be found in the neighboring CpG sites.
Pathway analysis of differentially methylated genes
For hypomethylated genes identified by the microarray analysis, pathway analysis revealed
that these genes were highly associated with co-expression networks of type I interferon,
including “response to type I interferon” (FDR = 1.45e-34), “type I interferon-mediated signal-
ing pathway” (FDR = 1.45e-34), and “cellular response to type I interferon” (FDR = 1.45e-34)
(Fig 5). There was no significant pathway enrichment found for the 7 hypermethylated genes.
DNA methylation level and gene expression
To investigate the effect of DNA methylation loss on gene expression, real-time PCR analysis
was performed for MX1, IFI44L,NLRC5 and PLSCR1 in the same cohort of individuals
recruited for the bisulfite pyrosequencing analysis. The mRNA expression of these genes was
significantly higher in the SLE patients than in the controls (Fig 6). Moreover, we found that the
degree of methylation of the CpG sites identified in the microarray study was inversely corre-
lated with mRNA expression (S6 Fig). The effect of DNA methylation of the CpG sites sur-
rounding the one identified in the microarray study on mRNA expression was also investigated.
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In the case of MX1 (S7 Fig), the methylation levels of the surrounding hypomethylated CpG
sites (CpG2- CpG7) were compared to that of CpG1 and found to be correlated (r2 value = 0.66)
with mRNA expression. However, in the case of NLRC5 (S8 Fig), the methylation status of the
surrounding CpG sites (CpG1- CpG6) did not correlate with the one identified by the microar-
ray analysis. Some of the surrounding CpG sites, such as CpG3 and CpG4, did show a weak cor-
relation with mRNA expression. The r2 value ranged from 0.06 to 0.26.
Fig 3. Volcano plot showing DNA methylation data according to genomic distribution. Blue spots
represent CpG sites that are considered to be differentially methylated, fulfilling the requirement of a beta
difference > |0.1| and log transformed adjusted p-value > 1.3, whereas red spots represent CpG sites that are
not differentially methylated. (A) CpG sites are classified in relation to CpG islands. Most of the differentially
methylated probes are located in shores and non-islands. (B) CpG sites are classified in relation to the gene
structure, and most of the differentially methylated CpG sites are located in the 5’UTR, 1500 bp upstream of the
TSS and in the gene body.
doi:10.1371/journal.pone.0169553.g003
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Discussion
Our data contribute three new findings to the current literature. First, the epigenetic deregula-
tion seen in Caucasian individuals with SLE can also be observed in Chinese SLE patients,
although the prevalence of SLE is much higher in Chinese populations. In our study, genes
exhibiting a loss of methylation in SLE patients were found to be overrepresented in type I
interferon pathways. This finding is interesting but not totally surprising because the impor-
tance of type I interferon in SLE has been addressed and suggested for disease pathogenesis for
several decades. For example, serum type I interferon is increased in patients with SLE [30],
and the level of these proteins correlates with disease activity and severity [31]. Our initial
screen for SLE candidate differentially methylated regions was performed in a small number
of SLE patients (n = 12) but was then replicated in a much bigger cohort of SLE patients
(n = 100). Usually, but not always, the level of DNA methylation is inversely correlated with
gene expression [32, 33]. Moreover, the effect of hypomethylation on SLE patients has rarely
been investigated in genome-wide DNA methylation studies. We therefore also tested the effect
of the loss of methylation on gene expression in whole blood, and chose four genes with vali-
dated DNA methylation differences for further mRNA expression analysis in the same cohort
of 100 patients and 100 controls. For all four genes, regardless of the location (promoter, CpG
Fig 4. Comparison of the methylation level of four hypomethylated genes between control and SLE patients. Bisulfite
pyrosequencing was carried out on four of the genes that were found to be differentially methylated in the 450k microarray and
in a larger cohort of 100 SLE patients and 100 healthy controls. These genes are MX1, IFI44L, NLRC5 and PLSCR1. Bisulfite
pyrosequencing of all four genes confirmed the microarray findings, showing that SLE patients have a significant loss of
methylation when compared to healthy controls.
doi:10.1371/journal.pone.0169553.g004
Genome-Wide DNA Methylation Analysis of Chinese Patients with SLE Identified Hypomethylation
PLOS ONE | DOI:10.1371/journal.pone.0169553 January 13, 2017 9 / 17
shores) of the altered CpG sites, DNA hypomethylation was associated with a statistically signif-
icant increase in mRNA expression in SLE patients. In fact, many hypomethylated genes identi-
fied in our study have already been reported in the literature to have increased expression in
SLE patients. For example, MX1, LY6E, IFIT1, PLSCR1 and IRF7were up-regulated in Cauca-
sian SLE patients [34–36]; MX1, LY6E, and IFIT1, as well as OAS1 and OAS3, were up-regulated
in Chinese SLE patients [37–40]; and IFITM1was up-regulated in the platelets of Caucasian
SLE patients [41]. All the above genes represent type I interferon up-regulated genes [42]. As
the differentially hypomethylated genes found in our microarray study were enriched in type I
interferon co-expression pathways, our study further supports the importance of type I inter-
feron in SLE in the Chinese population. Although Asians have a higher prevalence of SLE than
Caucasians, the same hypomethylation signature can be identified, therefore such hypomethyla-
tion is thought to represent the epigenetic predisposition to SLE that is independent of ethnicity.
To investigate when this gene-specific hypomethylation occurs, it would be interesting to carry
out long term follow-up studies of people at high risk of SLE (e.g., first-degree relatives of indi-
viduals with SLE) to see if they also develop hypomethylation of type I interferon-related genes
prior to the onset of SLE.
Second, such epigenetic deregulation can be defined in unfractionated white blood cells. To
date, three studies assessing genome-wide DNA methylation in Caucasian populations using
the 450k microarray have been conducted to study the epigenetic abnormalities in specific
blood cell lineages. Absher et al. investigated the genome-wide DNA methylation changes in
CD4+ T cells, CD19+ B cells and CD14+ monocytes [20], whereas Coit et al. first studied the
Fig 5. Co-expression analysis of differentially hypomethylated genes. The differentially hypomethylated genes
found in the 450k microarray study were input into GeneMANIA for co-expression analysis, which revealed that they are
related to type I interferon pathways, including “response to type I interferon” (FDR = 1.45e-34), “type I interferon-
mediated signaling pathway” (FDR = 1.45e-34) and “cellular response to type I interferon” (FDR = 1.45e-34). Genes
identified in these three co-expression pathways are overlapped with each other and are indicated in blue circles. Black
circles indicate the differentially hypomethylated genes found in the 450k microarray, whereas circles with alternating
black and blue stripes indicate hypomethylated genes that are overrepresented in type 1 interferon pathways.
doi:10.1371/journal.pone.0169553.g005
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DNA methylation alterations in naïve CD4+ T cells [21] and furthered this analysis in neutro-
phils [22]. Though different blood cell lineages were studied, the same epigenetic signature
showing hypomethylation in interferon genes were identified. Here, we demonstrated that
fractionation of different white blood cells was not required to visualize this pattern of DNA
methylation changes. In fact, among the 36 differentially hypomethylated CpG sites identified
in our study, 35 of them were also reported in at least one of these three studies. This finding
further suggests that the hypomethylated CpG sites identified in our study are the commonly
altered CpG sites in SLE patients, regardless of ethnicity and blood cell subtype. The limitation
of studying unfractionated white blood cells is that lineage-specific DNA methylation changes
cannot be revealed; however, DNA from unfractionated white blood cells can be collected
more easily, as only small volume of blood is needed, which is more acceptable to the recruited
patients.
The third new finding we contribute is that we found an interesting pattern with respect to
the genomic location of DNA hypomethylation. CpG sites showing loss of methylation were
usually not located in a CpG island but rather in a CpG shore, which is the region approxi-
mately 0–2 kb away from a CpG island. Early discoveries demonstrated that DNA methylation
changes can be associated with human disease through changes in DNA methylation at sites
located either in gene promoters or CpG islands only [43, 44]. Then, a study of colon cancer
Fig 6. Comparison of the mRNA expression of the four validated genes between SLE patients and controls.
mRNA expression level measurement of the four validated genes, MX1, IFI44L, PLSCR1 and NLRC5, was carried out in
a cohort of 100 controls and 100 SLE patients. The mRNA expression level of all four genes were higher in SLE patients
than in controls.
doi:10.1371/journal.pone.0169553.g006
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revealed that functional changes occurred in CpG shores as well. It was also found that CpG
shores, rather than CpG islands, are associated with most tissue-specific differential DNA
methylation [45]. Since then, DNA methylation changes that occur in CpG shores have been
identified in other diseases, such as breast cancer, hepatocellular carcinoma and type 2 diabe-
tes. In fact, it is now evident that more CpG sites showing aberrant changes in DNA methyla-
tion are located in CpG shores than in CpG islands [46–48]. Our finding also suggests the
functional importance of DNA methylation in CpG shores. We also looked at the DNA meth-
ylation data of different normal tissues obtained from the ENCODE project using the UCSC
Genome Browser and found that in general, differentially methylated CpG sites located in
CpG shores showed a distinct DNA methylation level between different tissues, whereas differ-
entially methylated CpG sites located in regions other than CpG shores showed more or less
the same DNA methylation level among different tissues (S9 Fig). The tissue-specific DNA
methylation pattern located in CpG shores suggests its biological potential in determining tis-
sue-specific functions, and loss of the original DNA methylation status in specific tissues could
indicate the diseased stage of the cell.
Among the hypomethylated genes discovered in SLE patients, more and more attention is
now focusing on IRF7. IRF7 belongs to the family of interferon regulatory factors, encoding
interferon regulatory factor 7. The interferon regulatory factors are well-known transcriptional
regulators of type I interferon and the type I interferon-inducible genes [49]. Studies in a
murine model demonstrated that IRF7 is an essential master regulator for the production of
type I interferon [50]. IRF7 is activated by interaction with the adaptors MyD88 and TRAF6,
which in turn results in activation of the interferon-alpha gene promoter [50–52]. Further-
more, various genome-wide studies from different ethnic groups identified genetic variations
in and around the coding region of IRF7 that are associated with SLE [53, 54].
IFI44L is also another important gene that exhibits DNA methylation loss. It is known that
type I interferon stimulates the expression of IFI44L, though the function of IFI44L remains
unknown [55]. However, numerous studies found that IFI44Lwas hypomethylated in SLE
patients [20–22], and recently Zhao et al. proposed that IFI44L promoter methylation can be
used as a biomarker for distinguishing patients with SLE from healthy controls, and also other
autoimmune diseases such as primary Sjo¨gren’s syndrome and rheumatoid arthritis [56].
These results show that epigenetic analysis also provides opportunities for identifying novel
biomarkers in SLE, and other epigenetic mechanisms, including histone modifications,
5-hydroxymethylcytosine and microRNA, have recently been reported to be dysregulated in
SLE patients [57, 58]. These studies show that epigenetic factors, in addition to genetic factors,
also play a role in SLE pathogenesis.
Conclusion
In summary, our study of DNA methylation in unfractionated white blood cells demonstrated
that in Chinese SLE patients from Hong Kong, differential DNA hypomethylation replicates
the DNA methylation changes in Caucasian patients from whom fractionated white blood
cells were tested for DNA methylation. DNA methylation changes occurred in gene-specific
regions, especially CpG shores, and the genes were over-represented in type I interferon path-
ways, thus supporting the importance of type I interferon dysregulation in SLE pathogenesis.
Supporting Information
S1 Fig. Sequences flanking the differentially methylated CpG sites. The sequences flanking
the differentially methylated CpG sites in MX1, IFI44L, PLSCR1 and NLRC5 are shown. All the
differentially methylated CpG sites identified by the 450k microarray within the transcription
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start site of these genes are indicated, and the corresponding CG nucleotides in the sequence
are underlined and highlighted in red.
(TIF)
S2 Fig. Boxplot showing the average beta of control and SLE patients. There are a total of
48,578 probes on the 450k microarray, and 10 controls and 12 SLE patients were included for
the downstream analysis. The box plot of the average beta for both the control group and SLE
group is shown. There is no significant difference between control and SLE patients.
(TIF)
S3 Fig. Hypermethylated genes found in SLE patients. Differentially hypermethylated genes
are shown in the histogram, with the average beta of individuals of control and SLE patients.
(TIF)
S4 Fig. Effect of blood cell type composition on the SLE DNA methylation signature. The
DNA methylation signature of 12 SLE patients and 10 controls overlapping the 44 differen-
tially methylated CpG sites was compared to the DNA methylation status at the same CpG
sites from 48 different blood cell types from Reinius et al. Principal component analysis
showed the distribution of these samples based on their DNA methylation profiles, in which
all normal blood samples, including purified blood subtypes, were well separated from the SLE
samples.
(TIF)
S5 Fig. Methylation level of MX1 and NLRC5. In addition to the differentially methylated
CpG site detected by the microarray study, bisulfite pyrosequencing was also used to measure
the DNA methylation level of CpG sites surrounding the differentially methylated one. (A)
Boxplot showing the DNA methylation level of 7 CpG sites of MX1. The differentially methyl-
ated CpG site detected by microarray is CpG1. (B) Boxplot showing the DNA methylation
level of 7 CpG sites of NLRC5. The differentially methylated CpG site detected by microarray
is CpG7.
(TIF)
S6 Fig. Effect of DNA methylation on mRNA expression of MX1, IFI44L, PLSCR1 and
NLRC5. Red spots refer to the data obtained from SLE patients, whereas blue spots refer to the
data obtained from controls. The effect of DNA methylation of the differentially hypomethy-
lated CpG sites identified in the microarray study on mRNA expression was studied, and it
was demonstrated that mRNA expression was inversely correlated with DNA methylation
level in MX1, IFI44L, PLSCR1 and NLRC5.
(TIF)
S7 Fig. Effect of the methylation of CpG sites on MX1mRNA expression. Red spots refer to
the data obtained from SLE patients, whereas blue spots refer to the data obtained from con-
trols. CpG1 is the differentially hypomethylated CpG site identified in the microarray study,
whereas CpG2-CpG7 are the CpG sites surrounding CpG1. The data reveal that the methyla-
tion of sites CpG2-CpG7 correlate with mRNA expression more or less to the same extent as
methylation of CpG1.
(TIF)
S8 Fig. Effect of the methylation of CpG sites on NLCR5 mRNA expression. Red spots
refer to the data obtained from SLE patients, whereas blue spots refer to the data obtained
from controls. CpG7 is the differentially hypomethylated CpG site identified in the microarray
study, whereas CpG1-CpG6 are the CpG sites surrounding CpG1. The data reveal that the
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methylation of CpG1- CpG6 correlate differently to mRNA expression as compared to methyl-
ation of CpG1.
(TIF)
S9 Fig. 450k microarray data collected by the UCSC Genome Browser. The 450k DNA
methylation data of different normal tissues were searched in ENCODE. In general, CpG sites
located in CpG shores showed a more variable DNA methylation level in different tissues com-
pared to those located in regions other than CpG shores. Only hypomethylated genes detected
in our 450k microarray study and those CpG sites with relations to CpG islands are shown.
(TIF)
S1 Table. Clinical information of the 12 SLE patients participating in the microarray
study.
(DOCX)
S2 Table. Bisulfite pyrosequencing assay design.
(DOCX)
S3 Table. Differentially methylated CpG sites identified in our study.
(DOCX)
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